Skip to main
MGX
MGX logo

Metagenomi Inc (MGX) Stock Forecast & Price Target

Metagenomi Inc (MGX) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Metagenomi Inc. has demonstrated a robust performance in its gene editing initiatives, achieving durable FVIII levels of 80% at the 19-month mark in non-human primate studies, indicating significant potential for its Hemophilia A treatment (MGX-001). The company's proprietary genome editing toolbox, which includes advanced systems for both small and large genetic edits, underscores its competitive positioning in the biopharmaceutical sector. With a focused pipeline targeting serious disorders and a dual strategy of in vivo gene editing and technology out-licensing for ex vivo therapies, Metagenomi is well-positioned for future growth and innovation in genetic medicine.

Bears say

Metagenomi Inc reported a net loss of $19.9 million for the second quarter of 2025, equating to $0.54 per share, indicating a substantial financial strain. The company's pipeline, while ambitious, faces significant risks including potential delays in clinical assessments and the possibility of unfavorable clinical data, particularly for key candidates like MGX-001 targeting Hemophilia A. Additionally, there are concerns related to long-term dilution risk, which could further affect investor confidence and the company's financial stability.

Metagenomi Inc (MGX) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Metagenomi Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Metagenomi Inc (MGX) Forecast

Analysts have given Metagenomi Inc (MGX) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Metagenomi Inc (MGX) has a Strong Buy consensus rating as of Nov 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Metagenomi Inc (MGX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.